, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality … important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma … post-1997 chemotherapy innovation did not exceed $45,551. We also investigate the impact of chemotherapy innovation on the …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) — about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health … ; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health … ; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-adjusted mortality rates of residents of Germany, using longitudinal, annual, state-level data during the period 2000-2007. The estimates …-adjusted cancer mortality rates of residents of France, using longitudinal, annual, cancer-site-level data during the period 2002 …

This paper investigates the impact of the introduction of new orphan drugs on premature mortality from rare diseases … estimate models using two alternative definitions of premature mortality, several alternative criteria for inclusion in the set … of rare diseases, and several values of the potential lag between new drug approvals and premature mortality reduction …